GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Neovasc Inc (NAS:NVCN) » Definitions » Shares Outstanding (Diluted Average)

Neovasc (Neovasc) Shares Outstanding (Diluted Average) : 2.75 Mil (As of Dec. 2022)


View and export this data going back to 2008. Start your Free Trial

What is Neovasc Shares Outstanding (Diluted Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Neovasc's average diluted shares outstanding for the quarter that ended in Dec. 2022 was 2.75 Mil.


Neovasc Shares Outstanding (Diluted Average) Historical Data

The historical data trend for Neovasc's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neovasc Shares Outstanding (Diluted Average) Chart

Neovasc Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shares Outstanding (Diluted Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.26 0.67 2.52 2.73

Neovasc Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Shares Outstanding (Diluted Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.71 2.71 2.73 2.75 2.75

Neovasc Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Neovasc  (NAS:NVCN) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Neovasc Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of Neovasc's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Neovasc (Neovasc) Business Description

Industry
Traded in Other Exchanges
N/A
Address
13562 Maycrest Way, Suite 5138, Richmond, BC, CAN, V6V 2J7
Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.

Neovasc (Neovasc) Headlines

From GuruFocus

Neovasc Comments on European Heart Journal Publication

By Value_Insider Value_Insider 11-18-2022

Neovasc to Participate in H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 06-12-2022

Neovasc to Participate in H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 06-22-2022

Neovasc Announces Progress on COSIRA-II Clinical Trial

By Value_Insider Value_Insider 11-28-2022

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

By GuruFocusNews GuruFocusNews 07-05-2022

Neovasc to Report Third Quarter Financial Results on November 10, 2022

By Value_Insider Value_Insider 10-27-2022